XTNTHIGH SIGNALFINANCIAL10-K

XTNT reports a substantial revenue decline coupled with higher gross profit, indicating a fundamental shift in business mix driven by the loss of SimpliMax licensing revenue.

The company explicitly warns that $18.7 million in license revenue from 2025 will likely not repeat in 2026 due to reimbursement changes affecting SimpliMax, creating significant headwinds for future performance. This revenue mix shift, while temporarily boosting margins, signals potential challenges in maintaining growth momentum and suggests the company may need to accelerate other growth initiatives to offset the licensing revenue loss.

Comparing 2026-03-31 vs 2025-03-06View on EDGAR →
FINANCIAL ANALYSIS

XTNT's financials reflect a mixed but concerning picture, with revenue declining 17.5% while gross profit grew 23.5%, indicating a dramatic improvement in product mix but at the cost of overall scale. The balance sheet strengthened meaningfully with total debt cut in half to $11.0M and stockholders' equity rising to $51.0M, while inventory reduction of 21.7% and lower capex suggest the company is rightsizing operations. The combination of revenue headwinds and balance sheet improvement suggests XTNT is navigating a transition period that prioritizes profitability over growth.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
-50%
$22.0M→$11.0M

Debt reduced 50% — deleveraging strengthens balance sheet and reduces financial risk.

Capital Expenditure
Cash Flow
-42.1%
$4.1M→$2.4M

Capex reduced 42.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Gross Profit
P&L
+23.5%
$68.2M→$84.3M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Inventory
Balance Sheet
-21.7%
$38.6M→$30.3M

Inventory reduced 21.7% — lean inventory management or demand outpacing supply.

Stockholders Equity
Balance Sheet
+18.6%
$43.0M→$51.0M

Equity base grew 18.6% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Revenue
P&L
-17.5%
$64.7M→$53.3M

Revenue softened 17.5% — monitor whether this is cyclical or structural.

Current Assets
Balance Sheet
+16.6%
$67.1M→$78.2M

Current assets grew 16.6% — improving short-term liquidity or inventory/receivables build.

Total Liabilities
Balance Sheet
-15.1%
$50.9M→$43.2M

Liabilities reduced 15.1% — deleveraging improves balance sheet strength and financial flexibility.

Accounts Receivable
Balance Sheet
-13.8%
$20.7M→$17.8M

Receivables declined — improved collection efficiency or conservative revenue recognition.

R&D Expense
P&L
-11.9%
$2.4M→$2.1M

R&D spending cut 11.9% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-06
ADDED
In addition, Xtant s biologics are utilized in trauma, foot and ankle, sports medicine, total joint, along with several surgical repair and wound care applications.
While our focus is the United States market, we promote and sell our products internationally through stocking distribution partners in Europe, Canada, Mexico, South America, and certain Pacific region countries.
We have recently made and intend to continue to make measured and targeted investments in the expansion of our commercial team to support our new products and maximize the reach of our broad portfolio of orthobiologics solutions.
Since one of our key growth initiatives is to leverage our growth platform with technology and strategic acquisitions and explore other strategic transactions with respect to our products and our company, including licenses, business collaborations and other business combinations or transactions with other companies, we, as a matter of course, often engage in discussions with third parties regarding such matters.
As discussed in more detail elsewhere in this report, we recognized $18.7 million in license revenue in 2025 that likely will not repeat in 2026 due primarily to changes in the reimbursement environment for our SimpliMax product effective January 1, 2026 and which changes also will adversely affect a portion of our product revenue in 2026.
+7 more — sign up free →
REMOVED
While our focus is primarily the United States market, we promote and sell our products internationally through direct sales representatives and stocking distribution partners in Europe, Canada, Mexico, South America, Australia, and certain Pacific region countries.
Our strategic focus is currently on digesting and growing the products and businesses we have acquired, producing our own stem cells, growth factor, amnio and synthetics biologics products, and continuing to focus on the following four key growth initiatives: (1) introduce new biologics products, including our Cortera Spinal Fixation System, viable bone matrix, OsteoVive Plus, and amniotic membrane allografts, SimpliGraft and SimpliMax ; (2) leverage our distribution network; (3) penetrate adjacent markets; and (4) leverage our growth platform with technology and strategic acquisitions.
Recent Developments During the fourth quarter of 2024, we entered into a license agreement with a distributor granting an exclusive, nontransferable, non-sublicensable, royalty-bearing right and license to manufacture and commercialize in the United States our SimpliMax product and the trademarks associated therewith during the term of the agreement and subject to certain limitations as set forth therein.
Under the terms of the agreement, we received a one-time, up front, non-refundable, non-creditable cash payment of $1.5 million.
Beginning in 2025, we are entitled to quarterly royalty payments based on the volume of product sold by the distributor.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →